Dorsa Jahangiri, M. Ardalan, M. Mubarak, S. Alimohammadi, H. Jahantigh, Sanam Saeifar
{"title":"Crescentic glomerulonephritis in a man with a history of methamphetamine abuse; a possible cause for concern","authors":"Dorsa Jahangiri, M. Ardalan, M. Mubarak, S. Alimohammadi, H. Jahantigh, Sanam Saeifar","doi":"10.34172/npj.2022.10508","DOIUrl":"https://doi.org/10.34172/npj.2022.10508","url":null,"abstract":"<jats:p>\u0000 </jats:p>","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44587137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dorsa Jahangiri, M. Ardalan, M. Mubarak, S. Alimohammadi, H. Jahantigh, Sanam Saeifar
{"title":"Kidney in chronic uncontrolled hypertension; mind the dual pathology","authors":"Dorsa Jahangiri, M. Ardalan, M. Mubarak, S. Alimohammadi, H. Jahantigh, Sanam Saeifar","doi":"10.34172/npj.2022.10507","DOIUrl":"https://doi.org/10.34172/npj.2022.10507","url":null,"abstract":"<jats:p>\u0000 </jats:p>","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43440909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H. Yousefi, M. Hosseinifard, Mojgan Falaki, Fariba Asadi Noghabi, H. Samimagham, Mohsen yousefi, H. Mardanparvar, J. Vahdatnejad
Introduction: Maintenance of hemodialysis catheters is essential for the patients and medical staff due to their repeated use for hemodialysis and other therapeutic interventions in the hospital. Objectives: This study aimed to comprise the effect of ethanol 70%-heparin versus cefazolin-heparin on the catheter durability time of hemodialysis patients. Patients and Methods: The study population consisted of 73 hemodialysis patients referred to Shahid Mohammadi hospital in Bandar Abbas. Patients were divided into two groups cefazolin (cefazolin 5 mg/dL, and heparin 2500 IU/mL) and ethanol (ethanol 70%, and heparin 2500 IU/mL). In both groups, after each hemodialysis session, 2.9 to 3.3 ml of the locking solution was locked in the catheter lumen and remained until the next session. This intervention was conducted for all patients continuously for five months. The time of catheter durability was calculated from the time of catheter placement in the central vein until the time that it has been taken out according to the doctor’s diagnosis. Data were collected and analyzed by SPSS version 26. Results: Results showed that demographic characteristics, including age, weight, gender, marital status, catheter type, underlying diseases, and dialysis adequacy between the two groups were similar (P>0.05). In the ethanol group, the mean time of the catheter durability was 27.5 days, and in the cefazolin group was 26.98 days. Although the time of the catheter durability was slightly higher in the ethanol group, this difference was not significant (P=0.194). Conclusion: Cefazolin and ethanol 70% did not show a significant difference in the catheter durability time of hemodialysis patients. Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (IRCT20210811052145N1; https://en.irct.ir/trial/58037, ethical code; IR.HUNS.REC.1398.052).
{"title":"Durability of the two-lumen catheter in hemodialysis patients, which combination has a better effect, ethanol 70%-heparin or cefazolin-heparin: a randomized, double-blind clinical trial study","authors":"H. Yousefi, M. Hosseinifard, Mojgan Falaki, Fariba Asadi Noghabi, H. Samimagham, Mohsen yousefi, H. Mardanparvar, J. Vahdatnejad","doi":"10.34172/npj.2022.10526","DOIUrl":"https://doi.org/10.34172/npj.2022.10526","url":null,"abstract":"Introduction: Maintenance of hemodialysis catheters is essential for the patients and medical staff due to their repeated use for hemodialysis and other therapeutic interventions in the hospital. Objectives: This study aimed to comprise the effect of ethanol 70%-heparin versus cefazolin-heparin on the catheter durability time of hemodialysis patients. Patients and Methods: The study population consisted of 73 hemodialysis patients referred to Shahid Mohammadi hospital in Bandar Abbas. Patients were divided into two groups cefazolin (cefazolin 5 mg/dL, and heparin 2500 IU/mL) and ethanol (ethanol 70%, and heparin 2500 IU/mL). In both groups, after each hemodialysis session, 2.9 to 3.3 ml of the locking solution was locked in the catheter lumen and remained until the next session. This intervention was conducted for all patients continuously for five months. The time of catheter durability was calculated from the time of catheter placement in the central vein until the time that it has been taken out according to the doctor’s diagnosis. Data were collected and analyzed by SPSS version 26. Results: Results showed that demographic characteristics, including age, weight, gender, marital status, catheter type, underlying diseases, and dialysis adequacy between the two groups were similar (P>0.05). In the ethanol group, the mean time of the catheter durability was 27.5 days, and in the cefazolin group was 26.98 days. Although the time of the catheter durability was slightly higher in the ethanol group, this difference was not significant (P=0.194). Conclusion: Cefazolin and ethanol 70% did not show a significant difference in the catheter durability time of hemodialysis patients. Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (IRCT20210811052145N1; https://en.irct.ir/trial/58037, ethical code; IR.HUNS.REC.1398.052).","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49378922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mohammad-Reza Hajian, H. Jahantigh, S. Alimohammadi, Z. Mojtahedi, N. Kianpour, M. Foroutan
{"title":"Nirmatrelvir, a novel medication for COVID-19 treatment","authors":"Mohammad-Reza Hajian, H. Jahantigh, S. Alimohammadi, Z. Mojtahedi, N. Kianpour, M. Foroutan","doi":"10.34172/npj.2022.10486","DOIUrl":"https://doi.org/10.34172/npj.2022.10486","url":null,"abstract":"<jats:p>\u0000 </jats:p>","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43330257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F. Yaghoubi, F. Tavakoli, F. Ghanbari, N. Aghdami, D. Babakhani
Coronavirus disease 2019 (COVID-19) mainly manifests with flu-like and respiratory symptoms such as fever, chill, myalgia, cough, dyspnea and in severe cases, it leads to acute respiratory distress syndrome and respiratory failure. However, there is evidence of extra-pulmonary involvements in patients with COVID-19. Some case reports and studies have reported severe and life-threatening complications related to COVID-19 such as cardiovascular complications (acute heart failure, myocarditis, acute coronary syndrome, thromboembolic events) and neuromuscular complications (stroke, transient ischemic attack, myositis, myopathy, Guillain-Barre syndrome). Here, we report a 51-year-old woman without a previous history of cardiovascular disease or neuromuscular disease referred to the emergency department of our hospital with new onset severe respiratory distress and progressive symmetric quadriparesis. We concluded that, the patient was infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and we therefore have encountered acute myocarditis and acute myopathy due to COVID-19 disease. In the intensive care unit (ICU), the patient was treated with oxygen therapy without mechanical ventilation, dexamethasone, intravenous human immunoglobulin (IVIG), beta interferon and remdesivir. The clinical feature, cardiac, respiratory, neuromuscular and hemodynamic parameters improved clearly five days after taking above mentioned treatments. The troponin, N-terminal pro-B type natriuretic peptide (NTproBNP), creatine phosphokinase (CPK), returned to normal values. Following improvement of cardiac and neurologic problems, the patient was transferred from ICU to general ward and then after 10 days, she was discharged with oral anticoagulant, anti-platelet, low-dose of corticosteroids and other conservative treatments.
{"title":"Acute myocarditis and acute myopathy as the first manifestations of COVID-19; a case report","authors":"F. Yaghoubi, F. Tavakoli, F. Ghanbari, N. Aghdami, D. Babakhani","doi":"10.34172/npj.2022.10479","DOIUrl":"https://doi.org/10.34172/npj.2022.10479","url":null,"abstract":"Coronavirus disease 2019 (COVID-19) mainly manifests with flu-like and respiratory symptoms such as fever, chill, myalgia, cough, dyspnea and in severe cases, it leads to acute respiratory distress syndrome and respiratory failure. However, there is evidence of extra-pulmonary involvements in patients with COVID-19. Some case reports and studies have reported severe and life-threatening complications related to COVID-19 such as cardiovascular complications (acute heart failure, myocarditis, acute coronary syndrome, thromboembolic events) and neuromuscular complications (stroke, transient ischemic attack, myositis, myopathy, Guillain-Barre syndrome). Here, we report a 51-year-old woman without a previous history of cardiovascular disease or neuromuscular disease referred to the emergency department of our hospital with new onset severe respiratory distress and progressive symmetric quadriparesis. We concluded that, the patient was infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and we therefore have encountered acute myocarditis and acute myopathy due to COVID-19 disease. In the intensive care unit (ICU), the patient was treated with oxygen therapy without mechanical ventilation, dexamethasone, intravenous human immunoglobulin (IVIG), beta interferon and remdesivir. The clinical feature, cardiac, respiratory, neuromuscular and hemodynamic parameters improved clearly five days after taking above mentioned treatments. The troponin, N-terminal pro-B type natriuretic peptide (NTproBNP), creatine phosphokinase (CPK), returned to normal values. Following improvement of cardiac and neurologic problems, the patient was transferred from ICU to general ward and then after 10 days, she was discharged with oral anticoagulant, anti-platelet, low-dose of corticosteroids and other conservative treatments.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49425056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Diabetes is a common disease with several macro-vascular and microvascular complications, which can result in long-term damage of various organs. Health-related quality of life (HRQOL) is commonly impaired in patients suffering from prolonged diseases. Inadequate attention to HRQOL leads to decreased compliance with treatment and health-care interventions. Objectives: This study was aimed to identify possible determinants of HRQOL in Iranian people with type 2 diabetes mellitus (T2DM). Patients and Methods: A cross-sectional study of 160 patients with T2DM registered at endocrinology clinic of the Alzahra teaching hospital of Isfahan university of medical sciences, Iran, was conducted in 2019-2020. HRQOL was measured using the Short Form 36 Health Survey Questionnaire (SF-36). Multivariate linear regression models were used to analyze the variables associated with HRQOL. Results: A total of 160 patients took part in this study. The mean age of the respondents was 59.3 (9.9) years. Around 107 patients (66.9%) were women. The mean (SD) for sub-scales of SF-36 in all patients were physical functioning 57.1(32.5), role limitation due to physical health 62.4 (42.1), role limitation due to emotional health 82.3 (35.8), energy/fatigue 58.8 (21.4), emotional well-being 72.5 (17.5), social functioning 80.4 (28.3), pain 70.5 (26.9) and general health 46.9 (26.3). The most common factors contributing to lower SF-36 subscales were being female, having a higher body mass index (BMI), and having macro-vascular complications. Conclusion: HRQOL among Iranian people with T2DM is mostly influenced by gender, weight, and diabetes complications. By reducing complications of diabetes, especially macrovascular complications, and implementing obesity prevention policies, HRQOL could be improved. A patient-centered approach is needed to improve HRQOL for each patient.
{"title":"Predictors of health-related quality of life among Iranian people with type 2 diabetes","authors":"Maryam Alamdari, R. Sajad, Rezvan Salehidoost","doi":"10.34172/npj.2022.10501","DOIUrl":"https://doi.org/10.34172/npj.2022.10501","url":null,"abstract":"Introduction: Diabetes is a common disease with several macro-vascular and microvascular complications, which can result in long-term damage of various organs. Health-related quality of life (HRQOL) is commonly impaired in patients suffering from prolonged diseases. Inadequate attention to HRQOL leads to decreased compliance with treatment and health-care interventions. Objectives: This study was aimed to identify possible determinants of HRQOL in Iranian people with type 2 diabetes mellitus (T2DM). Patients and Methods: A cross-sectional study of 160 patients with T2DM registered at endocrinology clinic of the Alzahra teaching hospital of Isfahan university of medical sciences, Iran, was conducted in 2019-2020. HRQOL was measured using the Short Form 36 Health Survey Questionnaire (SF-36). Multivariate linear regression models were used to analyze the variables associated with HRQOL. Results: A total of 160 patients took part in this study. The mean age of the respondents was 59.3 (9.9) years. Around 107 patients (66.9%) were women. The mean (SD) for sub-scales of SF-36 in all patients were physical functioning 57.1(32.5), role limitation due to physical health 62.4 (42.1), role limitation due to emotional health 82.3 (35.8), energy/fatigue 58.8 (21.4), emotional well-being 72.5 (17.5), social functioning 80.4 (28.3), pain 70.5 (26.9) and general health 46.9 (26.3). The most common factors contributing to lower SF-36 subscales were being female, having a higher body mass index (BMI), and having macro-vascular complications. Conclusion: HRQOL among Iranian people with T2DM is mostly influenced by gender, weight, and diabetes complications. By reducing complications of diabetes, especially macrovascular complications, and implementing obesity prevention policies, HRQOL could be improved. A patient-centered approach is needed to improve HRQOL for each patient.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48236875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alireza Pouramini, M. Khosravian, Fatemeh Kafi, Sina Bakhshaei, H. Jahantigh, P. Peymani, N. Kianpour, M. Foroutan
impairment. Additionally, Paxlovid requires Implication for health policy/practice/research/medical education: Paxlovid is an effective oral treatment for COVID-19 patients that reduces mortality and can be administered in an outpatient setting, but it cannot substitute COVID-19 immunizations.
{"title":"Hope and fear; Paxlovid for COVID-19 treatment: A Letter to the Editor","authors":"Alireza Pouramini, M. Khosravian, Fatemeh Kafi, Sina Bakhshaei, H. Jahantigh, P. Peymani, N. Kianpour, M. Foroutan","doi":"10.34172/npj.2022.10485","DOIUrl":"https://doi.org/10.34172/npj.2022.10485","url":null,"abstract":"impairment. Additionally, Paxlovid requires Implication for health policy/practice/research/medical education: Paxlovid is an effective oral treatment for COVID-19 patients that reduces mortality and can be administered in an outpatient setting, but it cannot substitute COVID-19 immunizations.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48687964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Meisam Moezzi, H. Motamed, Javad Mozafari, Majid Fattah, Ali Delirrooyfard
Introduction: Acute pain is a common symptom in patients with bone fractures referring to the emergency department (ED). Objectives: The present study aimed at evaluating the efficacy of intravenous (IV) magnesium sulfate in controlling acute pain of long-bone fractures in EDs. Patients and Methods: The present double-blind, randomized clinical trial was conducted on patients with isolated limb fractures referred to Golestan hospital of Ahvaz from 2019 to 2020. Patients in the intervention group were injected with 0.1 mg/kg morphine plus 30 mg/kg magnesium sulfate and 0.1 mg/kg morphine alone in the morphine group. The patient’s pain scores were measured at 0, 15, 30, 45 and 60 minutes after injection. The patients’ condition was monitored every 10 minutes, including respiratory and pulse rate, blood pressure, and knee reflex. Results: The present study was conducted on 64 patients with long-bone fractures allocated to two groups of IV morphine plus magnesium sulfate and IV morphine alone (each of 32). The hemodynamic factors and mean body temperature did not significantly change after intervention and had a similar level in both groups. Before the intervention, the mean score of pain was measured in the morphine and magnesium sulfate plus morphine groups using a visual analogue scale. Results which were 8.87±0.83 and 8.93±0.94, respectively, showing no significant differences (P=0.69). After 60 minutes, the pain score reduced considerably in both groups. Conclusion: In the study, magnesium sulfate plus morphine could better reduce pain than morphine alone without influencing the respiratory rate. Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (IRCT20190617043913N1; https://en.irct.ir/trial/40370, ethical code# IR.AJUMS.REC.1398.143).
{"title":"A comparison of magnesium sulfate plus morphine with morphine alone for acute pain reduction in long-bone fractures; a double blind randomized clinical trial","authors":"Meisam Moezzi, H. Motamed, Javad Mozafari, Majid Fattah, Ali Delirrooyfard","doi":"10.34172/npj.2022.10455","DOIUrl":"https://doi.org/10.34172/npj.2022.10455","url":null,"abstract":"Introduction: Acute pain is a common symptom in patients with bone fractures referring to the emergency department (ED). Objectives: The present study aimed at evaluating the efficacy of intravenous (IV) magnesium sulfate in controlling acute pain of long-bone fractures in EDs. Patients and Methods: The present double-blind, randomized clinical trial was conducted on patients with isolated limb fractures referred to Golestan hospital of Ahvaz from 2019 to 2020. Patients in the intervention group were injected with 0.1 mg/kg morphine plus 30 mg/kg magnesium sulfate and 0.1 mg/kg morphine alone in the morphine group. The patient’s pain scores were measured at 0, 15, 30, 45 and 60 minutes after injection. The patients’ condition was monitored every 10 minutes, including respiratory and pulse rate, blood pressure, and knee reflex. Results: The present study was conducted on 64 patients with long-bone fractures allocated to two groups of IV morphine plus magnesium sulfate and IV morphine alone (each of 32). The hemodynamic factors and mean body temperature did not significantly change after intervention and had a similar level in both groups. Before the intervention, the mean score of pain was measured in the morphine and magnesium sulfate plus morphine groups using a visual analogue scale. Results which were 8.87±0.83 and 8.93±0.94, respectively, showing no significant differences (P=0.69). After 60 minutes, the pain score reduced considerably in both groups. Conclusion: In the study, magnesium sulfate plus morphine could better reduce pain than morphine alone without influencing the respiratory rate. Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (IRCT20190617043913N1; https://en.irct.ir/trial/40370, ethical code# IR.AJUMS.REC.1398.143).","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43408659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F. Ghahremanfard, Gholam Ali Mahdavi, M. Mirmohammadkhani, Maliheh Yarmohammadi
Introduction: Intradialytic hypotension is an important and common complication of hemodialysis. However, it seems that selective serotonin reuptake inhibitors (SSRIs) can manage patients’ blood pressure during hemodialysis. Objectives: The present study aimed to investigate the effect of sertraline on intradialytic hypotension of the patients under hemodialysis. Patients and Methods: The present randomized controlled trial included 18 patients under hemodialysis for end-stage renal disease (ESRD). The patients were randomly divided into the intervention and control groups. The intervention group received sertraline solely for intradialytic hypotension management, while the control group did not receive such intervention. The blood pressure assessments were conducted before, during, and after hemodialysis in both groups, then the data were analyzed. Results: According to our results, the participants’ mean age was 63.72±9.91 years. The mean systolic and diastolic blood pressures were higher in the intervention group than in the control group before the hemodialysis. However, this difference was not significant for systolic blood pressure (P=0.279), while it was significant for diastolic blood pressure (P=0.02). Additionaly, no significant intergroup difference in systolic and diastolic blood pressure during and after hemodialysis was detected (P>0.05). Conclusion: Sertraline had no significant effect on systolic and diastolic blood pressure during and after hemodialysis. However, it increased the mean systolic and diastolic blood pressure before hemodialysis which could prevent pre-dialytic hypotension without significant side effects. Therefore, it can be effective in preventing hypotension in patients under hemodialysis. Trial Registration: The trial protocol has been approved by the Iranian Registry of Clinical Trial (identifier: IRCT2017080625732N23; https://en.irct.ir/trial/21499, ethical approval code; IR.SEMUMS.REC.1395.156).
{"title":"Effect of sertraline on intradialytic hypotension: a randomized controlled trial","authors":"F. Ghahremanfard, Gholam Ali Mahdavi, M. Mirmohammadkhani, Maliheh Yarmohammadi","doi":"10.34172/npj.2022.10492","DOIUrl":"https://doi.org/10.34172/npj.2022.10492","url":null,"abstract":"Introduction: Intradialytic hypotension is an important and common complication of hemodialysis. However, it seems that selective serotonin reuptake inhibitors (SSRIs) can manage patients’ blood pressure during hemodialysis. Objectives: The present study aimed to investigate the effect of sertraline on intradialytic hypotension of the patients under hemodialysis. Patients and Methods: The present randomized controlled trial included 18 patients under hemodialysis for end-stage renal disease (ESRD). The patients were randomly divided into the intervention and control groups. The intervention group received sertraline solely for intradialytic hypotension management, while the control group did not receive such intervention. The blood pressure assessments were conducted before, during, and after hemodialysis in both groups, then the data were analyzed. Results: According to our results, the participants’ mean age was 63.72±9.91 years. The mean systolic and diastolic blood pressures were higher in the intervention group than in the control group before the hemodialysis. However, this difference was not significant for systolic blood pressure (P=0.279), while it was significant for diastolic blood pressure (P=0.02). Additionaly, no significant intergroup difference in systolic and diastolic blood pressure during and after hemodialysis was detected (P>0.05). Conclusion: Sertraline had no significant effect on systolic and diastolic blood pressure during and after hemodialysis. However, it increased the mean systolic and diastolic blood pressure before hemodialysis which could prevent pre-dialytic hypotension without significant side effects. Therefore, it can be effective in preventing hypotension in patients under hemodialysis. Trial Registration: The trial protocol has been approved by the Iranian Registry of Clinical Trial (identifier: IRCT2017080625732N23; https://en.irct.ir/trial/21499, ethical approval code; IR.SEMUMS.REC.1395.156).","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47645261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F. Farnood, K. Boostani, S. M. Hejazian, M. Ardalan
Kidney transplantation is a definite treatment for end-stage renal disease (ESRD). However, management of allograft dysfunction has remained a major challenge and some patients return to dialysis after renal transplantation. Studies showed that peritoneal dialysis (PD) results in a higher chance of survival and a lower risk of delayed allograft dysfunction compared to hemodialysis (HD). For this reason, this study explored the initiation of PD in six patients with renal allograft dysfunction in Tabriz Imam Reza hospital (referral PD center). This case reported the results of PD and incremental PD among these patients with failed kidney transplantation. Creatinine and hemoglobin levels, duration of starting PD, PD exchange, PD modality, immunosuppressive drugs mortality rate and urine volume were evaluated during the study. In conclusion, although re-transplantation is a gold standard therapy in failed kidney transplant patients, PD or incremental PD could be a suitable and home-based modality for preserving renal function and urine output in these patients.
{"title":"Peritoneal dialysis after failed kidney transplantation; a case series with review of the literature","authors":"F. Farnood, K. Boostani, S. M. Hejazian, M. Ardalan","doi":"10.34172/npj.2022.10491","DOIUrl":"https://doi.org/10.34172/npj.2022.10491","url":null,"abstract":"Kidney transplantation is a definite treatment for end-stage renal disease (ESRD). However, management of allograft dysfunction has remained a major challenge and some patients return to dialysis after renal transplantation. Studies showed that peritoneal dialysis (PD) results in a higher chance of survival and a lower risk of delayed allograft dysfunction compared to hemodialysis (HD). For this reason, this study explored the initiation of PD in six patients with renal allograft dysfunction in Tabriz Imam Reza hospital (referral PD center). This case reported the results of PD and incremental PD among these patients with failed kidney transplantation. Creatinine and hemoglobin levels, duration of starting PD, PD exchange, PD modality, immunosuppressive drugs mortality rate and urine volume were evaluated during the study. In conclusion, although re-transplantation is a gold standard therapy in failed kidney transplant patients, PD or incremental PD could be a suitable and home-based modality for preserving renal function and urine output in these patients.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41772342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：